Business Context and Reporting Period
This Form 8-K is filed by Second Sight Medical Products, Inc. (Note: Request metadata listed "Vivani Medical, Inc." but the filing text identifies the registrant as Second Sight Medical Products, Inc.) for the reporting period ending March 27, 2017. The filing primarily addresses the listing of warrants from a recently completed rights offering and provides details on the capital raised.
Key Financial Metrics
- Capital Raised: Gross proceeds of approximately $20.1 million; net proceeds of about $19.7 million after costs and fees.
- Units Sold: 13,652,341 units, each consisting of one share of common stock and one warrant.
- Subscription Price: $1.47 per unit.
- Warrant Exercise Price: $1.47 per share.
- Outstanding Equity (as of March 14, 2017): 56,365,629 shares of common stock and 13,652,341 warrants.
- Liquidity/Trading: Warrants approved for listing on Nasdaq under symbol "EYESW" with trading scheduled to begin March 29, 2017.
Note: The filing does not provide specific values for revenue, profit, cash flow, operating margins, or existing debt levels.
Material Changes
The primary material change is the completion of the Rights Offering announced on March 10, 2017, and the subsequent approval for the warrants to trade on Nasdaq. This transaction significantly increased the company's cash position by approximately $19.7 million in net proceeds and expanded the outstanding share count.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard terms of the warrant agreement. Key terms regarding the warrants include:
- Term: Five years, expiring March 14, 2022.
- Redemption: Warrants may be called for redemption at $0.01 per warrant on 30 days' notice if: (i) 24 months have passed since issuance; (ii) the stock trades at 200% or more of the subscription price for 15 consecutive trading days; and (iii) independent directors vote in favor.
Investor Verification Checklist
- Verify the ticker symbols "EYES" (common stock) and "EYESW" (warrants) on Nasdaq.
- Confirm the exact net proceeds of $19.7 million were deposited and utilized as intended.
- Monitor the stock price relative to the $1.47 exercise price to assess the likelihood of warrant redemption or exercise.
- Review the full press release (Exhibit 99.1) for any additional details on the use of proceeds not included in this summary.